{
    "info": {
        "nct_id": "NCT04178967",
        "official_title": "A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.",
        "inclusion_criteria": "* Male or female adults and adolescents (≥12 years and ≥40 kg)\n* Chronic atopic dermatitis (according to American Academy of Dermatology Consensus Criteria) that has been present for ≥1 year before the screening visit\n* Eczema Area and Severity Index (EASI) score ≥16 at the baseline visit\n* Investigator Global Assessment (IGA) score ≥3 (scale of 0 to 4) at the baseline visit\n* ≥10% body surface area (BSA) of atopic dermatitis involvement at the baseline visit\n* History of inadequate response to treatment with topical medications; or determination that topical treatments are otherwise medically inadvisable\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
        "exclusion_criteria": "* Prior treatment with dupilumab or tralokinumab\n* Treatment with topical corticosteroids, calcineurin inhibitors or phosphodiesterase-4 inhibitors such as crisaborole within 1 week prior to the baseline visit\n* Treatment with any of the following agents within 4 weeks prior to the baseline visit:\n\n  * Immunosuppressive/immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate-mofetil, IFN-γ, Janus kinase inhibitors, azathioprine, methotrexate, etc.)\n  * Phototherapy and photochemotherapy (PUVA) for AD\n* Treatment with the following prior to the baseline visit:\n\n  * An investigational drug within 8 weeks or within 5 half-lives (if known) of baseline, whichever is longer\n  * Cell-depleting biologics, including to rituximab, within 6 months of baseline\n  * Other biologics within 5 half-lives (if known) or 16 weeks of baseline, whichever is longer\n* Treatment with a live (attenuated) vaccine within 12 weeks of the baseline visit or planned during the study\n* Uncontrolled chronic disease that might require bursts of oral corticosteroids, e.g., co-morbid severe uncontrolled asthma\n* Evidence of active acute or chronic hepatitis\n* History of human immunodeficiency virus (HIV) infection or positive HIV serology\n* History of malignancy, including mycosis fungoides, within 5 years before the screening visit, except completely treated in situ carcinoma of the cervix, completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin\n* Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Chronic atopic dermatitis (according to American Academy of Dermatology Consensus Criteria) that has been present for ≥1 year before the screening visit",
            "criterions": [
                {
                    "exact_snippets": "Chronic atopic dermatitis (according to American Academy of Dermatology Consensus Criteria)",
                    "criterion": "chronic atopic dermatitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "diagnostic criteria",
                            "expected_value": "American Academy of Dermatology Consensus Criteria"
                        }
                    ]
                },
                {
                    "exact_snippets": "has been present for ≥1 year before the screening visit",
                    "criterion": "duration of atopic dermatitis",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Investigator Global Assessment (IGA) score ≥3 (scale of 0 to 4) at the baseline visit",
            "criterions": [
                {
                    "exact_snippets": "Investigator Global Assessment (IGA) score ≥3 (scale of 0 to 4) at the baseline visit",
                    "criterion": "Investigator Global Assessment (IGA) score",
                    "requirements": [
                        {
                            "requirement_type": "value at baseline visit",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "(scale of 0 to 4)"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of inadequate response to treatment with topical medications; or determination that topical treatments are otherwise medically inadvisable",
            "criterions": [
                {
                    "exact_snippets": "History of inadequate response to treatment with topical medications",
                    "criterion": "response to topical medications",
                    "requirements": [
                        {
                            "requirement_type": "response adequacy",
                            "expected_value": "inadequate"
                        }
                    ]
                },
                {
                    "exact_snippets": "determination that topical treatments are otherwise medically inadvisable",
                    "criterion": "topical treatments",
                    "requirements": [
                        {
                            "requirement_type": "medical advisability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eczema Area and Severity Index (EASI) score ≥16 at the baseline visit",
            "criterions": [
                {
                    "exact_snippets": "Eczema Area and Severity Index (EASI) score ≥16 at the baseline visit",
                    "criterion": "Eczema Area and Severity Index (EASI) score",
                    "requirements": [
                        {
                            "requirement_type": "value at baseline",
                            "expected_value": {
                                "operator": ">=",
                                "value": 16,
                                "unit": ""
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 12 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 12 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ≥10% body surface area (BSA) of atopic dermatitis involvement at the baseline visit",
            "criterions": [
                {
                    "exact_snippets": "≥10% body surface area (BSA) of atopic dermatitis involvement at the baseline visit",
                    "criterion": "atopic dermatitis involvement",
                    "requirements": [
                        {
                            "requirement_type": "extent (body surface area)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "timepoint",
                            "expected_value": "baseline visit"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male or female adults and adolescents (≥12 years and ≥40 kg)",
            "criterions": [
                {
                    "exact_snippets": "Male or female",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "adults and adolescents (≥12 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum_age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "≥40 kg",
                    "criterion": "weight",
                    "requirements": [
                        {
                            "requirement_type": "minimum_weight",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "kg"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Uncontrolled chronic disease that might require bursts of oral corticosteroids, e.g., co-morbid severe uncontrolled asthma",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled chronic disease that might require bursts of oral corticosteroids",
                    "criterion": "chronic disease",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "likelihood of requiring oral corticosteroids",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "co-morbid severe uncontrolled asthma",
                    "criterion": "asthma",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with a live (attenuated) vaccine within 12 weeks of the baseline visit or planned during the study",
            "criterions": [
                {
                    "exact_snippets": "Treatment with a live (attenuated) vaccine within 12 weeks of the baseline visit",
                    "criterion": "treatment with live (attenuated) vaccine",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "weeks before baseline visit"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "planned during the study",
                    "criterion": "planned treatment with live (attenuated) vaccine",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "during the study"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cell-depleting biologics, including to rituximab, within 6 months of baseline",
            "criterions": [
                {
                    "exact_snippets": "Cell-depleting biologics, including to rituximab, within 6 months of baseline",
                    "criterion": "cell-depleting biologics (including rituximab) administration",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study",
            "criterions": [
                {
                    "exact_snippets": "Pregnant ... women",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding women",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "women planning to become pregnant ... during the study",
                    "criterion": "intention to become pregnant during the study",
                    "requirements": [
                        {
                            "requirement_type": "intention",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "women planning to ... breastfeed during the study",
                    "criterion": "intention to breastfeed during the study",
                    "requirements": [
                        {
                            "requirement_type": "intention",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* An investigational drug within 8 weeks or within 5 half-lives (if known) of baseline, whichever is longer",
            "criterions": [
                {
                    "exact_snippets": "An investigational drug within 8 weeks or within 5 half-lives (if known) of baseline, whichever is longer",
                    "criterion": "prior investigational drug exposure",
                    "requirements": [
                        {
                            "requirement_type": "time since last exposure",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 8,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": ">",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Immunosuppressive/immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate-mofetil, IFN-γ, Janus kinase inhibitors, azathioprine, methotrexate, etc.)",
            "criterions": [
                {
                    "exact_snippets": "Immunosuppressive/immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate-mofetil, IFN-γ, Janus kinase inhibitors, azathioprine, methotrexate, etc.)",
                    "criterion": "immunosuppressive or immunomodulating drug use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with topical corticosteroids, calcineurin inhibitors or phosphodiesterase-4 inhibitors such as crisaborole within 1 week prior to the baseline visit",
            "criterions": [
                {
                    "exact_snippets": "Treatment with topical corticosteroids ... within 1 week prior to the baseline visit",
                    "criterion": "treatment with topical corticosteroids",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "week prior to the baseline visit"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Treatment with ... calcineurin inhibitors ... within 1 week prior to the baseline visit",
                    "criterion": "treatment with calcineurin inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "week prior to the baseline visit"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Treatment with ... phosphodiesterase-4 inhibitors such as crisaborole within 1 week prior to the baseline visit",
                    "criterion": "treatment with phosphodiesterase-4 inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "week prior to the baseline visit"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with dupilumab or tralokinumab",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with dupilumab",
                    "criterion": "prior treatment with dupilumab",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with ... tralokinumab",
                    "criterion": "prior treatment with tralokinumab",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with the following prior to the baseline visit:",
            "criterions": [
                {
                    "exact_snippets": "Treatment with the following prior to the baseline visit",
                    "criterion": "treatment prior to baseline visit",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Phototherapy and photochemotherapy (PUVA) for AD",
            "criterions": [
                {
                    "exact_snippets": "Phototherapy and photochemotherapy (PUVA) for AD",
                    "criterion": "phototherapy for atopic dermatitis",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "photochemotherapy (PUVA) for AD",
                    "criterion": "photochemotherapy (PUVA) for atopic dermatitis",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence of active acute or chronic hepatitis",
            "criterions": [
                {
                    "exact_snippets": "Evidence of active acute or chronic hepatitis",
                    "criterion": "hepatitis",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "acute",
                                "chronic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Other biologics within 5 half-lives (if known) or 16 weeks of baseline, whichever is longer",
            "criterions": [
                {
                    "exact_snippets": "Other biologics within 5 half-lives (if known) or 16 weeks of baseline, whichever is longer",
                    "criterion": "other biologics",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 16,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of human immunodeficiency virus (HIV) infection or positive HIV serology",
            "criterions": [
                {
                    "exact_snippets": "History of human immunodeficiency virus (HIV) infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "positive HIV serology",
                    "criterion": "HIV serology",
                    "requirements": [
                        {
                            "requirement_type": "serology result",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with any of the following agents within 4 weeks prior to the baseline visit:",
            "criterions": [
                {
                    "exact_snippets": "Treatment with any of the following agents within 4 weeks prior to the baseline visit",
                    "criterion": "treatment with specified agents",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to baseline visit"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* History of malignancy, including mycosis fungoides, within 5 years before the screening visit, except completely treated in situ carcinoma of the cervix, completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin",
            "criterions": [
                {
                    "exact_snippets": "History of malignancy, including mycosis fungoides, within 5 years before the screening visit",
                    "criterion": "history of malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except completely treated in situ carcinoma of the cervix",
                    "criterion": "in situ carcinoma of the cervix",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "completely treated"
                        }
                    ]
                },
                {
                    "exact_snippets": "except completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin",
                    "criterion": "non-metastatic squamous or basal cell carcinoma of the skin",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "completely treated and resolved"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}